Clinical Trial Update: Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 safety and biomarker study of RL-007 in subjects with schizophrenia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Schizophrenia

Drugs mentioned

• RL-007

Snippet

Sponsor: Recognify Life Sciences | Conditions: Cognitive Impairment, Schizophrenia | Phase 2 | Status: COMPLETED